Company Quick10K Filing
Biogen Idec
10-Q 2020-06-30 Filed 2020-07-22
10-Q 2020-03-31 Filed 2020-04-23
10-K 2019-12-31 Filed 2020-02-06
10-Q 2019-09-30 Filed 2019-10-22
10-Q 2019-06-30 Filed 2019-07-24
10-Q 2019-03-31 Filed 2019-04-24
10-K 2018-12-31 Filed 2019-02-06
10-Q 2018-09-30 Filed 2018-10-23
10-Q 2018-06-30 Filed 2018-07-24
10-Q 2018-03-31 Filed 2018-04-24
10-K 2017-12-31 Filed 2018-02-01
10-Q 2017-09-30 Filed 2017-10-24
10-Q 2017-06-30 Filed 2017-07-25
10-Q 2017-03-31 Filed 2017-04-25
10-K 2016-12-31 Filed 2017-02-02
10-Q 2016-09-30 Filed 2016-10-26
10-Q 2016-06-30 Filed 2016-07-21
10-Q 2016-03-31 Filed 2016-04-21
10-K 2015-12-31 Filed 2016-02-03
10-Q 2015-09-30 Filed 2015-10-21
10-Q 2015-06-30 Filed 2015-07-24
10-Q 2015-03-31 Filed 2015-04-24
10-K 2014-12-31 Filed 2015-02-04
10-Q 2014-09-30 Filed 2014-10-22
10-Q 2014-06-30 Filed 2014-07-23
10-Q 2014-03-31 Filed 2014-04-23
10-K 2013-12-31 Filed 2014-02-06
10-Q 2013-09-30 Filed 2013-10-28
10-Q 2013-06-30 Filed 2013-07-25
10-Q 2013-03-31 Filed 2013-04-25
10-K 2012-12-31 Filed 2013-02-05
10-Q 2012-09-30 Filed 2012-10-25
10-Q 2012-06-30 Filed 2012-07-24
10-Q 2012-03-31 Filed 2012-05-01
10-K 2011-12-31 Filed 2012-02-03
10-Q 2011-09-30 Filed 2011-10-28
10-Q 2011-06-30 Filed 2011-07-26
10-Q 2011-03-31 Filed 2011-04-21
10-K 2010-12-31 Filed 2011-02-04
10-Q 2010-09-30 Filed 2010-10-26
10-Q 2010-06-30 Filed 2010-07-20
10-Q 2010-03-31 Filed 2010-04-20
10-K 2009-12-31 Filed 2010-02-09
8-K 2020-07-22 Earnings, Exhibits
8-K 2020-07-16 Officers, Regulation FD, Exhibits
8-K 2020-06-18
8-K 2020-06-03
8-K 2020-04-27
8-K 2020-04-22
8-K 2020-04-20
8-K 2020-01-30
8-K 2020-01-28
8-K 2019-12-19
8-K 2019-10-22
8-K 2019-09-29
8-K 2019-07-23
8-K 2019-06-19
8-K 2019-05-09
8-K 2019-04-29
8-K 2019-04-24
8-K 2019-03-24
8-K 2019-01-29
8-K 2018-11-01
8-K 2018-10-23
8-K 2018-08-03
8-K 2018-07-24
8-K 2018-06-21
8-K 2018-06-12
8-K 2018-04-24
8-K 2018-01-25
8-K 2015-09-15
8-K 2015-09-10
8-K 2015-08-28
8-K 2015-07-24
8-K 2015-06-11
8-K 2015-04-23
8-K 2015-03-27
8-K 2015-01-29

Biogen Idec Financials

BIIB Metrics, Comps, Filings

Quarterly | Annual

Valuation ($BB)

Market Cap, Enterprise Value

Balance Sheet ($BB)

Assets, Equity

Income Statement ($BB Quarterly)

Revenue, G Profit, Net Income

Cash Flow ($BB Quarterly)

Ops, Inv, Fin

Comps ($MM TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Gilead Sciences (GILD) 84,019 79% 15.1 9% 61,627 39,102 22,449 17,774 5,386 6,432 96,981
Biogen Idec (BIIB) 43,857 86% 6.6 20% 27,484 13,492 14,233 12,236 5,396 6,986 45,971
Seattle Genetics (SGEN) 12,597 0% -42.8 -15% 2,098 318 801 0 -304 -290 12,404
Neurocrine Biosciences (NBIX) 9,277 80% 165.0 2% 1,180 605 676 539 21 55 9,105
Bio-Techne (TECH) 7,746 66% 42.0 5% 1,925 751 734 484 93 193 8,119
Qiagen (QGEN) 7,622 0% 5,748 3,113 0 0 0 0 8,637
Bluebird Bio (BLUE) 5,301 61% -7.0 -38% 1,892 421 54 33 -715 -704 4,946
Moderna (MRNA) 5,287 0% -13.8 -25% 1,591 339 82 0 -391 -369 5,101
Repligen (RGEN) 4,036 55% 78.3 2% 1,379 334 253 140 23 49 3,801
Autolus Therapeutics (AUTL) 3,969 0% -161.3 -8% 254 22 0 0 -21 -23 3,752
Spark Therapeutics (ONCE) 3,758 16% -14.2 -36% 704 357 70 11 -250 -250 3,548
Argenx (ARGX) 3,491 0% 578 40 0 0 0 0 3,489
Allogene Therapeutics (ALLO) 3,340 -18.1 -22% 696 76 0 0 -154 -152 2,738
China Biologic Products (CBPO) 2,933 64% 30.5 3% 2,010 165 186 119 69 85 2,594
Mesoblast (MESO) 2,543 0% 652 171 0 0 0 0 2,543
Crispr Therapeutics (CRSP) 2,445 0% -240.3 -2% 721 129 213 0 -11 -8 1,811
Acceleron Pharma (XLRN) 2,328 0% -16.2 -26% 520 55 38 0 -136 -133 2,157
Halozyme Therapeutics (HALO) 2,317 59% -78.1 -11% 370 125 203 119 -40 -29 2,267
Iovance Biotherapeutics (IOVA) 2,270 -11.5 -42% 396 41 0 0 -167 -166 1,908
Genetic Technologies (GENE) 1,880 0% 3 1 0 0 0 0 1,878

Balance Sheet ($MM)2009-12-312010-03-312010-06-302010-09-302010-12-312011-03-312011-06-302011-09-302011-12-312012-03-312012-06-302012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash5826407216277607916985755152984574525716633934286038298631,1861,2051,4781,2824,0891,3081,1311,3622,0852,3269241,1701,5481,5744,1081,2502,3871,2252,2431,7232,344
Accounts Receivable5515615496176056886675815856846846626877548618918241,0181,0021,0911,2921,3901,3111,3281,2271,3951,2931,4681,4421,5021,6301,5681,7871,9391,9512,0171,9582,0891,9601,934
Inventory2942802683083113273383633934475075706146596737167538048258669198939659961,0101,0029229361,007903891932917930770777752
PP&E1,6371,6051,5721,6422,4091,6741,7131,5722,3541,6171,6232,5752,6831,7371,7881,8062,8691,7441,7561,7242,9521,7401,8382,0283,5182,2592,3022,3873,9412,6112,8282,9964,7423,3353,4093,5395,3993,0143,0783,138
Assets8,5528,2177,5027,3948,0928,2948,6228,8029,0509,1149,1629,63110,13010,16510,84211,25011,86312,23012,91813,70414,31715,21916,75920,72819,50520,67521,51522,10522,87721,19621,75923,07323,65326,09023,95325,49225,28926,44626,28827,484
Accounts Payable119121144144163159171159186173159157204165163167220213225234229236283251267271226274280316330299396346296342370378377382
Long-Term Debt1,0801,0761,0701,0691,0661,0661,0631,0611,0616266426581,0217127266955925915865845825815766,5296,5606,5366,5386,5306,5565,9535,9545,9386,0035,9295,9285,9316,0005,9435,9484,458
Liabilities2,2902,2672,2912,3242,6432,6192,5662,5692,6232,8052,8922,9693,1662,8252,9393,1253,2423,0893,3533,2733,5033,5504,18610,16110,13010,34710,1119,99010,7489,72810,18510,22411,05412,05311,69911,73212,25712,62413,33913,492
Stockholders' Equity6,2225,9095,1715,0315,3975,6045,9776,2296,4256,3066,2686,6606,9627,3397,9028,1258,6209,1379,56110,42810,80911,66712,57310,5739,37310,32711,40412,11812,14011,47911,58512,86012,61314,05412,26113,76713,04013,83012,95313,996
Income Statement ($MM)2009-12-312010-03-312010-06-302010-09-302010-12-312011-03-312011-06-302011-09-302011-12-312012-03-312012-06-302012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Revenue1,1091,2131,1761,2191,2031,2361,3101,3271,2921,4211,3861,4181,4151,7531,8281,9662,1302,7232,5112,6412,5552,5922,7782,8392,7272,8942,9562,8722,8113,0783,0783,3073,1313,3563,4393,5263,4903,6173,600
Cost of Revenue9710796100103108124140133149139134134259297332378509421461488602476430
Gross Profit1,0121,1061,0801,1191,1001,1291,1861,1871,1591,2721,2461,2841,2811,7072,3432,5082,4942,7982,9362,9783,0382,8883,1403,170
R&D307332319291294286301339356384304345284327410422529447417500461491520542437473529534423796446588497981508564485540
SG&A249262244276245267261284300340300376353484406523512577570574560492478583497492463496499430434572501516498568588554
Tax75102757911713712710582121131136661591861901782692752682822933302573563543371902392703841,566322264370422248211
Net Income2202952542723093283543003033873982924275194884574807238578848239271,0198329711,0501,0336497488631,226-1661,1739151,4449471,4091,4941,546
Cash Flow ($MM)2009-12-312010-03-312010-06-302010-09-302010-12-312011-03-312011-06-302011-09-302011-12-312012-03-312012-06-302012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash Operating3374284284312544305714741956365425081796256728691059919149337331,0478951,0409639969871,5772351,1691,6281,5181,4571,0991,7361,4601,9641,695
Cash Investing250684-70-519-127-547-587-3901-53-522-375156-726-324-7106-630-541-378-503-1,253-990-1,808-1,203-73636-582-744-203-1,247-7701,347-1,148-619239-111-366
Cash Financing-523-1,026-461226-10022-99-143-416-417-28-16-238-171-31911115-322-35-51381-42,908-1,99847-13-301-721-901-751-20-708-269-2,79225-679-2,376-689